Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition – University of Bristol
University of Bristol |
Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition
University of Bristol 17 synthetic biology researchers received training and coaching on how to set up a biotech company using synthetic biology as part of the BrisSynBio 4-Day MBA ‘More Business Acumen’ course – developed by SynbiCITE. At the climax of the course, … |
Chaffey Breeze |
Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual …
GlobeNewswire (press release) WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, presented an update on its … CRISPR: The Future of Medicine and Human Evolution » in-Training …in-Training China racing ahead to beat cancer with CRISPR gene editingecns Insider Selling: Crispr Therapeutics AG (CRSP) CEO Sells $10422.72 in StockThe Cerbat Gem Sports Perspectives –Transcript Daily –Chaffey Breeze all 14 news articles » |
Chaffey Breeze |
Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual …
GlobeNewswire (press release) WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, presented an update on its … CRISPR: The Future of Medicine and Human Evolution » in-Training …in-Training China racing ahead to beat cancer with CRISPR gene editingecns Insider Selling: Crispr Therapeutics AG (CRSP) CEO Sells $10422.72 in StockThe Cerbat Gem Sports Perspectives –Transcript Daily –Chaffey Breeze all 14 news articles » |
Nasdaq |
Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual …
Nasdaq WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, presented an update on its … CRISPR Therapeutics to Present at Investor Conferences in MayGlobeNewswire (press release) CRISPR: The Future of Medicine and Human Evolution » in-Training …in-Training China racing ahead to beat cancer with CRISPR gene editingecns The Cerbat Gem –Transcript Daily –Sports Perspectives all 19 news articles » |
Daily Mail |
Stem cell sticking plaster could beat heart failure
Daily Mail A sticking plaster made using stem cells harvested from a patient’s own thigh could be the key to beating heart failure. Researchers have mended damaged hearts using a tiny patch packed with the health-boosting cells. They glued the patch to the … |
|
Competition between immune cells could explain why some immunotherapy drugs fail
Cancer Research UK New images may have uncovered why in some cases cancers don’t respond to certain immunotherapy drugs. Research published in the journal Science Translational Medicine (link is external) found that, in mice, one type of immune cell competes with … |
|
Competition between immune cells could explain why some immunotherapy drugs fail
Cancer Research UK New images may have uncovered why in some cases cancers don’t respond to certain immunotherapy drugs. Research published in the journal Science Translational Medicine (link is external) found that, in mice, one type of immune cell competes with … |